In a report released yesterday, Kallum Titchmarsh from Morgan Stanley maintained a Sell rating on Embecta Corporation (EMBC – Research Report), ...

BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded ...

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...

After adding nearly 30% in the previous session following its better-than-expected Q4 results for FY24, Embecta (NASDAQ:EMBC) ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

Q4 2024 Earnings Call Transcript November 26, 2024 Embecta Corp. misses on earnings expectations. Reported EPS is $ EPS, ...

Embecta also said it expects to earn between $2.70 and $2.90 a share on an adjusted basis for all of 2025, easily surpassing the average analyst estimate of $2.27 per share. Revenue is anticipated at ...

Embecta Corp (EMBC) reports a 4.1% revenue increase while navigating restructuring and future growth opportunities.

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” ...

Embecta EMBC is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors ...

Q4 2024 Earnings Conference Call November 26, 2024 8:00 AM ETCompany ParticipantsPravesh Khandelwal - VP of IRDev Kurdikar ...